Clinical Trials Logo

Cardiomyopathies clinical trials

View clinical trials related to Cardiomyopathies.

Filter by:

NCT ID: NCT05214365 Recruiting - Clinical trials for Conduction System Pacing

Physiological Pacing for AV Block to Prevent Pacemaker-induced Cardiomyopathy

PHYSPAVB
Start date: February 1, 2022
Phase: N/A
Study type: Interventional

The implantation of a pacemaker and conventional cardiac pacing from the right ventricle (apex or septum) is an effective and safe therapy for the treatment of patients with atrioventricular block and bradycardia.

NCT ID: NCT05210010 Enrolling by invitation - Clinical trials for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

A Prospective Study to Assess the Utility of CA-4F in a Canadian Cardiology Setting

Start date: November 1, 2021
Phase: N/A
Study type: Interventional

This study will assess whether CA-4F can improve diagnosis of ATTR-CM in a community cardiology setting when used to screen electronic medical record data for patients suitable for follow-up investigations.

NCT ID: NCT05209776 Recruiting - Clinical trials for Arrhythmogenic Right Ventricular Dysplasia

Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy

LI-ARVC
Start date: February 1, 2022
Phase: N/A
Study type: Interventional

The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation. The present study aim to document the feasibility of detecting the potential presence of intracardiac local inflammatory components in patients with ARVC.

NCT ID: NCT05201014 Recruiting - Cancer Clinical Trials

Cancer Survivor Cardiomyopathy Detection

CASCADE
Start date: March 3, 2022
Phase:
Study type: Observational

The purpose of this study is to improve the cardiovascular care of adult cancer survivors. The goal is to obtain the data necessary to plan and develop a nation-wide network of a screening program that can help provide cost-effective and long-term monitoring.

NCT ID: NCT05194865 Not yet recruiting - Clinical trials for Ischemic Cardiomyopathy

Coronary Revascularization Based on CMR Viability Study Vs Direct Revascularization in Ischemic Cardiomyopathy Patients

Start date: February 1, 2022
Phase:
Study type: Observational

The study aiming to demonstrate the baseline characteristics and outcomes of patients undergoing revascularization by PCI vs those kept only on medical treatment, based on CMR viability assessment.

NCT ID: NCT05193838 Not yet recruiting - Clinical trials for Dilated Cardiomyopathy

Effect of Allopurinol on Left Ventricular Function in Children With Dilated Cardiomyopathy

Start date: May 1, 2022
Phase:
Study type: Observational

The aim of this study is to detect effect of allopurinol supplementation in pediatric patients with dilated cardiomyopathy.

NCT ID: NCT05186818 Completed - Clinical trials for Obstructive Hypertrophic Cardiomyopathy (oHCM)

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM (SEQUOIA-HCM)

SEQUOIA-HCM
Start date: February 1, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction

NCT ID: NCT05184296 Recruiting - Septic Shock Clinical Trials

ExtraCorporeal Membrane Oxygenation in the Therapy for REfractory Septic Shock With Cardiac Function Under Estimated

ECMO-RESCUE
Start date: May 1, 2023
Phase: N/A
Study type: Interventional

The ECMO-RESCUE study is a prospective, multicenter, non-randomized, cohort study. In this study, we aimed to assessed whether VA-ECMO treatment can improve the 30-day survival rate of patients with sepsis-induced refractory cardiogenic shock.

NCT ID: NCT05182658 Recruiting - Heart Failure Clinical Trials

Empagliflozin in Hypertrophic Cardiomyopathy

EMPA-REPAIR
Start date: June 1, 2022
Phase: Phase 3
Study type: Interventional

The proposed intervention will be administration of empagliflozin at a standard dose of 10 mg daily for a period of 12 months. Patients with diagnosed diabetes will be excluded from the study. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group. The primary endpoint of the study will be the change in peak oxygen uptake (VO2 max) measured in a cardiopulmonary exercise test. VO2max is an objective indicator of physical performance and will be evaluated before and after empagliflozin or placebo treatment.

NCT ID: NCT05181631 Not yet recruiting - Diabetes Clinical Trials

Diabetic/Metabolic Cardiomyopathy: Prevalence and Phenotype

METAB-HEART
Start date: January 15, 2022
Phase: N/A
Study type: Interventional

"Little is known about the prevalence, determinants and phenotypes of the cardiomyopathy associated with diabetes and/or metabolic syndrome. The emergence of new therapies (SGLT2 inhibitors) that may mitigate and even prevent the onset of heart failure offers new opportunities.The objective of this protocol is to evaluate the prevalence and phenotypes of cardiomyopathy confirmed by echography in people at high metabolic risk defined as living with diabetes or obesity."